CA
NZ
UK
AU
IND
US
CVKD stands out among the day's decliners after a 9.14% drop that pulled the price toward $3.18. A 9.14% fall left Cadrenal Therapeutics, Inc. (CVKD) firmly in negative territory, with the stock priced near $3.18. The decline in Cadrenal Therapeutics, Inc. adds to the …
Shares of Cuprina Holdings (Cayman) (CUPR) ended the session sharply lower, with the stock down 10.07% and changing hands near $3.93. Investors may be watching CUPR closely after the company shed 10.07% of its value in a single session. It is worth stressing that …
It is worth stressing that a 8.94% fall can either extend further or reverse quickly, and CNSP is no exception. CNSP stands out among the day's decliners after a 8.94% drop that pulled the price toward $4.28. A 8.94% fall left CNS Pharmaceuticals, Inc. …
One catalyst to monitor is whether the 13.45% decline in BJDX reflects company-specific concern or a wider rotation out of similar names. Heightened volatility around BJDX suggests that some holders chose to reduce exposure after the $3.86 level came under strain. The market may …
Investors may be watching BFLY closely after the company shed 18.31% of its value in a single session. Possible drivers behind the 18.31% move in Butterfly Network, Inc. (BFLY) range from profit-taking to a broader shift in risk appetite. One catalyst to monitor is …
Catheter Precision, Inc. (NYSE American: VTAK) shares advanced 16.94% to $1.03 in pre-market trading on June 23, 2026, as of the latest available update. The stock had ended the previous session at $0.88, up 1.18%.
Hims & Hers Health (NYSE: HIMS) shares declined 4.53% to $32.02 in pre-market trading on June 23, 2026, as of the latest available update. The decline followed a 5.44% fall during Monday’s regular session, when the stock closed at $33.54.
Beam Therapeutics (NASDAQ: BEAM) shares advanced 3.24% to $36.68 in pre-market trading on June 23, 2026, as of the latest available update. The move followed a 4.07% increase in the previous session, when the stock closed at $35.53.
Oruka Therapeutics, Inc. (NASDAQ:ORKA) advanced sharply as investors reassessed the value of differentiated psoriasis assets following a major sector transaction.
The Breakthrough Therapy Designation accelerates the regulatory review pathway and entitles Praxis to more intensive FDA guidance during development. SCN2A-DEE represents a high unmet need population where current standard-of-care options provide limited seizure control, making the designation strategically significant for the programme and for …
Please wait processing your request...